(Reuters) – AstraZeneca said on Tuesday it had agreed to buy China-based Gracell Biotechnologies to support its cell therapy ambitions, in a deal valued at approximately $1.2 billion.
(This story has been refiled to correct AstraZeneca’s spelling in the headline)
(Reporting by Urvi Dugar in Bengaluru; Editing by Sonia Cheema)
